COVID-19 in Pacific Experiences to date, where to from here?


Pacific Update
Development Policy Centre
24 September 2021



Dr Meru Sheel
Senior Research Fellow
National Centre for Epidemiology and Population Health
e: meru.sheel@anu.edu.au | > @merusheel







Affiliations & Declaration of Interests

- Deployed/ consult with the World Health Organization & Global Outbreak Alert and Response Network (GOARN)
- Consult with Jhpiego (a John Hopkins Affiliate)
- Member of the Australian Regional Immunisation Alliance
- Presenting in personal capacity

The Australian Regional Immunisation Alliance (ARIA)



ARIA: Australia's leading experts (30+) with a breadth and depth of experience in immunisation and VPDs. Connected to offer greater capacity

Our goal: work collaboratively with governments, global immunisation partners, non-government organisations and other partners to strengthen and to expand immunisation to reduce the impact of VPDs in our region


Secretariat and current chair: @NCIRS

Regional Immunisation Support and Engagement:


Funding from the DFAT Indo-Pacific Centre for Health Security, through the Pacific Infectious Disease Prevention (PIDP) Program 2020-2022



Figure 2. COVID-19 cases per 100 000 population reported by countries, territories and areas, 13 - 19 September 2021**



[&]quot;See Annex 2: Data. table and fiaure notes





Preparedness & response pillars



National Coordination and Planning



Surveillance, rapid response & case investigation





Risk communication and engagement



Laboratory diagnosis



Points of Entry
Border control &
quarantine



Infection prevention and control



Operations and logistics



Clinical management





COVID-19 Preparedness in Pacific Island Countries

Key challenges/ risk assessment, February 2020

- Risk of importation
- Risk of transmission
- Health system capacity to respond
 - Testing
 - Contact tracing
 - Isolation and quarantine
 - Hospital systems
 - Workforce
- Vaccine roll-out

INSIDE DEVELOPMENT | COVID-19

Is the Pacific ready for coron

By Lisa Cornish // 28 February 2020


Global Health Trade & Policy SPC WHO East Asia and Pacific



Medical staff at work in a hospital on the Marshall Islands. Photo by: ADB / CC BY-NC-ND



COVID-19 in the Pacific, 22 September 2021




^{*} Date of diagnosis is used when available



COVID-19 in Papua New Guinea, 12 September 2021


Epidemiology

Figure 3. Epidemiological curve of total COVID-19 cases in Papua New Guinea as at 12th September, 2021



Please note: The true extent of the decreasing trend must be interpreted with caution as there are delays in receiving and reporting results from provinces.

Figure 4: Tests done in the last 7 days, 06th to 12th September 2021






Barriers and enablers experienced by health care workers for testing of COVID-19

COVID-19 training for PNGDF, June 2020



PC: WHO Country Office, Papua New Guinea



Strategies for prevention & control of COVID-19 in the context of Pacific


Lessons learnt from easing COVID-19 restrictions: an analysis (1) (1) of countries and regions in Asia Pacific and Europe



Emeline Han*, Melisa Mei Jin Tan*, Eva Turk, Devi Sridhar, Gabriel M Leunq, Kenji Shibuya, Nima Asqari, Juhwan Oh, Alberto L García-Basteiro, Johanna Hanefeld, Alex R Cook, Li Yang Hsu, Yik Ying Teo, David Heymann, Helen Clark, Martin McKee, Helena Legido-Quigley


- Border control works
- Mask use is possible
- Health systems can be overwhelmed
 - Workforce
- Surveillance and testing
- Contact tracing and quarantine
 - Multi-generational households
- Public health and social measures
 - Lockdown vs targeted approach
 - When and how to ease the restrictions
 - Social & well-being support









COVID-19 vaccine introduction, faster than ever before



COVID-19 vaccine roll out, 21 September 2021



- Date and vaccine type varies by country.
- Proportions not based on eligible age cohort





COVID-19 vaccine roll-out in the Pacific

- Delayed start as part of the COVAX deliveries (April vs Feb) 66 days between first HIC and LMIC (Ghana)
- Logistical considerations: greater proportion shipped and expanded regional dose sharing from Australia and New Zealand; to maximise access from logistics of dispersed small island countries (compared with Africa/ Asia – 3% HCWs)
 - An opportunity to vaccinate in the absence of disease
- Community engagement: vaccine uptake, hesitancy and mis-information
- Progress monitoring: coverage and vaccine safety surveillance
- Lessons learnt from the recent measles outbreak

Healt

Tonga's extra doses, means more can get vaccinated



Thursday, April 29, 2021 - 18:49. Updated on Friday, April 30, 2021 - 09:50.

Thursday, April 29, 2021 - 18:49

Tonga's precious supply of covid vaccine can now be extended to thousands more people thanks to the skills of the Tongan nurses, who have the first batch received this month. People aged 35 years and over can now be vaccinated with the AstraZeneca COVID-19 vaccine. By Eleano







PACIFIC / FIJI

Supported by the Commonwealth Foundation under the "Sirengthering Citizen Engagement in COVID-19 Policy and Decision-making" Project

Better understanding of Covid-19 vaccine hesitancy in Fiji needed for succesful youth roll out - Study


7:45 pm on 6 September 2021



A civil society group in Fiji say the success of a Covid-19 vaccine rollout to Fijians und understanding of the reasons for hesitancy in Fiji.




Fig 19: Social media platforms used for COVID-19 related news





Emerging issues around policy & regulation




Breakthrough disease, boosters

What is the implication of breakthrough infections on severe outcome, long COVID19
Who needs a booster and when



VPD integrated campaigns postponed due to COVID-19: 46 countries with at least one VPD campaign postponed, 1st September 2021

Angola, Brazil, CAR, DR Congo, Mexico, Nigeria, Pakistan, Philippines, Somalia, Sudan, Viet Nam and Zimbabwe have re-instated campaigns with multi-antigens.







Where to from here?

- Public health response is complex and requires sub-regional, country-specific, multisectoral approach: agility across policy and implementation will be critical
- Vaccinate rapidly to ensure reduced morbidity and mortality
- Prepare for importation of COVID-19 in countries (endemicity), Delta strain likely to arrive in most countries
- Contact tracing and quarantine in vaccinated populations
- Booster doses and paediatric doses
- Vaccine registration and recall for additional doses
- Protecting the health system, and plan for interruption of routine immunisation and health services
- Scale-up in the context of plateauing uptake; accounting for misinformation community engagement
- Learn and document lessons from the roll-out of COVID19 vaccines for integration, strengthen the health system



Conclusions

 COVID-19 vaccines work but their inclusion into public health response measures requires creative solutions to ensure accelerated and equitable delivery

 Non-pharmaceutical interventions will be an integral part of response to COVID-19.

 Pacific island countries and territories are in a unique place to minimise morbidity and mortality from COVID-19.



Thank you & questions





